Zhou Chengjun
Deputy Director General, Research Bureau of PBoC;
Research Scholar and Professor of PBoC
Mr. Zhou Chengjun started his career at the People’s Bank of China (PBoC, China’s Central Bank) in 2003. He worked as a post-doctorate at PBoC’s Research Institute of Banking and Finance from July 2003 to July 2005. From 2005 to 2015, he worked in PBoC’s General Administration Office, writing intensively on central bank policy and drafting key policies and research documents for PBoC. Most critically, he served as the secretary and the academic adviser to Governor Zhou Xiaochuan from September 2009 to April 2015. Mr. Zhou was designated as Deputy Head of the General Administration Office from August 2013 to April 2015. From April 2015 to January 2017, he had been performing as Deputy Director General of the Monetary Policy Department Ⅱ of PBoC. Since January 2017, he has been serving as the deputy head of the Research Bureau of PBoC. And among which, for the whole year of 2017, he was working as a senior research associate and visiting scholar at Harvard Kennedy School. Additionally, Mr. Zhou has also been working as a research scholar and professor at the Research Institute of Banking and Finance of PBoC, and the University of International Business and Economics since 2011.
In June 2012, Mr. Zhou Chengjun won the National May Fourth Medal, which is one of the highest national honors to China’s youth. His research area included macroeconomics and monetary policy, reform of China’s economic and financial system, and the RMB internationalization and relevant policies. Since 2000, Mr. Zhou has published nearly seventy academic papers and essays in journals including Social Science in China and Financial Research. He is also the author of A Research on Macroeconomic effect of the Asset Price Fluctuation in China as in Constitutional Transition Period, published by Economic Science Publisher in 2004. Mr. Zhou Chengjun is the member of the China Financial Forum and the special member of China Finance 40 Forum.
Born in 1975, Mr. Zhou received his Bachelor Degree in Power Engineering in 1997 and a Master Degree in Finance in 2000 from Southeast University; and a Ph.D in Economics in 2003 from Nanjing University.
李丰
峰瑞资本创始合伙人
李丰侧重于高科技、TMT、新消费等领域的投资。他主导投资了三只松鼠、Unity、360金融、顺顺留学、清陶能源、两点十分、Robby、停简单等公司。
加入峰瑞资本前，李丰曾于IDG资本担任合伙人。在此期间，他主导投资的项目包括宜信、猪八戒、铜板街、Bilibili、Coinbase、轻轻家教、挖财、河狸家、英语流利说、同盾科技、Ripple Labs、闪银、江小白、韩都衣舍、百分点、百融等一系列优秀创业公司。
李丰拥有北京大学化学理学学士学位与美国罗彻斯特大学化学理学硕士学位。他获评投中集团“2015年度中国最佳移动互联网产业投资人物TOP10”、华兴资本“2017年度最佳天使投资人”“2016年度影响力投资人”、新浪科技“2017中国顶级投资人排行榜Top50”、36氪“最具创业者欢迎的VC投资人”“新金融&新消费领域10大投资人”。
Li Feng Founding Partner
Feng focuses on Deep Tech, TMT, consumption upgrade. He led investments on Three Squirrels, Unity, 360 Finance, Qingtao Energy, Shunshun Education, 2:10 Animation, Easy Parking, Robby, and XtaiPl among others.
Previously as a partner at IDG-Accel, he led investments on a series of successful projects, including CreditEase, Zhubajie, Prosper, Tongbanjie, Bilibili, Coinbase, Ripple Labs, Dig Fortune, Helijia, Wangli Finance Group, Yodo Fortune, FraudMetrix, Liulishuo, Wecash, Jiang Xiaobai, Hstyle, baifendian, and bairong. Among them, CreditEase went public in 2015, Zhubajie and Prosper successfully joined Billion Dollar Club. The return of investment at seed stage for Three Squirrels, Tongbanjie, and Wangli Finance Group are now up to 50 times.
Feng obtained B.S. in Chemistry from Peking University, and M.S. in Chemistry from University of Rochester.
杨云霞(Lynn Yang)
红杉资本中国基金董事总经理
杨云霞(Lynn Yang)主要专注于医疗健康领域的投资。
2015年5月加入红杉之前，杨云霞女士就职于君联资本医疗健康投资团队，主导完成了医疗健康多个细分行业的项目投资包括燃石医学，基石药业，Grail,香港亚洲医疗等。在此之前，杨女士曾经在美国强生，GE等大型跨国公司工作。
杨云霞女士拥有美国杜克大学(Duke University ) MBA学位及华中科技大学同济医科院临床医学硕士学位。
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry such as Burning Rock, Cstone,Grail,Hongkong Asia Medical etc. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare.
Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Raymond Fu,
Associate Professor and Serial Entrepreneur, Northeastern University
Raymond Fu is an associate professor at Northeastern University and a serial entrepreneur. His research interests focus on AI: Machine Learning, Computer Vision, Big Data, etc. He is Fellow of SPIE and IAPR. In 2016 he founded Giaran, Inc., a company that leverages advanced artificial intelligence technology developed in his Northeastern University lab with the goal of providing an interactive virtual experience for consumers to find and try on cosmetics products. In 2017, Giaran was acquired by Shiseido Americas Corporation, a subsidiary of the leading global cosmetics company Shiseido Company, Limited.
Gang Luo, PhD
Associate Professor of Ophthalmology，Harvard Medical School
Dr.Luo’s past experience as a research engineer, including his work with optics,image processing, and biomedical engineering, has influenced his interest inthe mechanisms of the human visual system. He studies assistive technology forindividuals with visual impairments. In particular, his current research includes the development of portable collision warning devices, includingsmartphone-based technologies, to improve walking mobility. He also studiesdriving behaviors in individuals with visual impairments.
He is currently the deputy director of the Qingdao Economic Development Committee of the Jiusan Society, the president of the Qingdao Shibei Science and Technology Promotion Association of the Jiusan Society, and the vice president of the Qingdao Commodity Trading Association. In 2011, he founded AVIC International Commodity Trading Center (Qingdao) Co., Ltd., whose main business is commodities Commodity trading and settlement. Business Administration, China University of Geosciences. EMBA from Peking University HSBC Business School.
Duncan Wong, PhD
Founder and CEO of CryptoBLK
Dr Duncan Wong is the Founder and CEO of CryptoBLK, a technology company focusing on building and operating Blockchain enterprise solutions for the global financial market. CryptoBLK is specializing in developing trade finance, and asset management platforms. CryptoBLK also has a Blockchain platform called DLTapp-as-a-Service (DaaS) which supports hybrid deployment on both cloud and on-premises.
Before founding CryptoBLK, Dr Wong was in charge of the Financial Technologies (FinTech) Initiative of the largest R&D Center in Hong Kong, the Hong Kong Applied Science and Technology Research Institute (ASTRI). The FinTech Initiative focused on Cybersecurity, Blockchain or Distributed Ledger Technology (DLT), Artificial Intelligence, Big Data Analytics, and Machine Learning.
Before joining ASTRI in 2014, Dr Wong had been a professor at the Chinese University of Hong Kong, then the City University of Hong Kong for 12 years, and tenured in the Department of Computer Science at City University of Hong Kong in 2009. Information Security, Cryptography, and Blockchain technologies are his primary R&D interests, in particular, cryptographic systems, encryption and digital signature, and crypto-currencies. Dr Wong has authored over 200 publications in Cryptography and Information Security, and has served as a member including the chair of the program committee for over 100 international conferences in cryptography and information security.
王世松博士是区块科技有限公司（CryptoBLK）的创始人兼首席执行官。CryptoBLK是一家专注开发及运营企业级区块链解决方案的技术公司。CryptoBLK的产品包括贸易融资和资产估值及管理平台，并提供DLTapp-as-a-Service（DaaS）的区块链平台服务，支持混合云端和就地部署。
在成立CryptoBLK之前，王博士在香港应用科技研究院（ASTRI）担任副总裁， 带领院内金融科技（FinTech）项目研发，包括网络安全，区块链，人工智能，大数据分析和机器学习。王博士曾任香港城市大学计算机科学系教授 (2003-2015)，博导超过十年，发表二百余篇关于密码学之研究文章与专利。
Wan Li Zhu
Partner at Fairhaven Capital
Wan Li Zhu is an experienced technology venture capital investor. Wan Li has been a Partner with Fairhaven Capital in Boston which has invested over $400M in enterprise software, hardware and consumer sectors. His recent investments have focused on AI-based expertise automation and marketplace platforms. Wan Li is Senior Advisor to Suffolk Construction on corporate venture capital, investing in construction and real estate technology companies. Wan Li founded and runs MIT Alumni Angels, MIT’s official alumni-based startup investment network with presence in Boston, New York, San Francisco and DC. Prior to venture capital, Wan Li ran product development and marketing organizations at Microsoft Dynamics CRM, which became the fastest growing business in the company’s history. He has also spent time at Google in online advertising, at Morgan Stanley in technology investment banking, and at Merrill Lynch in IT. Wan Li is the Executive Chairman of the New England Venture Network and has served as Chairman of MIT Enterprise Forum. Wan Li holds an MBA from Harvard, and Master’s and Bachelor’s degrees in Electrical Engineering and Computer Science from MIT where he completed research at the MIT Media Lab and Lab for Financial Engineering.
HUI HUANG, PHD, MBA
DRUG DEVELOPMENT VALUE & ACCESS EXPERT
FOUNDER & CEO, CSD-PARTNERS LLC HTTPS://CSD-PARTNERS.COM
EXPERIENCES
VICE PRESIDENT, HEAD OF GLOBAL VALUE & ACCESS ONCOLOGY • TAKEDA • 2019-2023
HEAD OF HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR)•TAKEDA ONCOLOGY/ARIAD/MILLENNIUM-TAKEDA• 2007-2019
SENIOR COMPUTATIONAL BIOLOGIST•GENOME THERAPEUTICS/AMBERGEN• 2000-2007
SERVICES
- Pre-IND +: BD & partnership; Portfolio & Indication strategy
- Ph1/2: Innovative trial design, protocol and analysis for Regulatory
approval, Pricing & Reimbursement; Early scientific advice, Medical
& Value Evidence Generation Plan (VGEP) - Peri-launch: Health Technology Assessment (HTA) strategy & filing;
Global Value Dossier (GVD) for Market Access and Reimbursement • Post-launch: Real-world data (RWD), evidence generation to
optimize life cycle for access and pricing
THOUGHT LEADERSHIP - Book Co-author: “Real World Evidence in Drug Development and Evaluation” (published by Taylor and Francis, 2021)
- Co-author: “Access in the New World”, 2021, https://www.pharmexec.com/view/access-in-the-new-world
- Co-author: World Economic Forum “A Global Roadmap for Health Informatics Standardization”, 2018
.